Financial Results for the Second Quarter Ended September 30, 2022
November 15, 2022
This is an English translation from Japanese presentation material.
Contents
- Consolidated Financial Results for the Second Quarter Ended September 30, 2022
- Consolidated Financial Forecast for the Year Ending March 31, 2023
- Business Progress and Future Measures
1
Consolidated Quarterly Financial Results for FY2023
(for the 2nd Quarter Ended September 30, 2022)
Actual | Y/Y | Comparison | ||
(million yen) | with May 12 | |||
forecast | ||||
Net sales | 32,587 | +1,035 | +4,842 | |
+3.3% | +17.5% | |||
[1] | 27,565 | +2,576 | +4,989 | |
Reagents | +10.3% | +22.1% | ||
Instruments | 694 | ▲17 | +25 | |
▲2.5% | +3.8% | |||
CDMO | 3,183 | ▲1,548 | ▲121 | |
▲32.7% | ▲3.7% | |||
Gene [2] | 1,144 | +26 | ▲50 | |
Therapy | +2.3% | ▲4.2% | ||
Gross | 22,025 | ▲1,470 | +2,338 | |
profit | ▲6.3% | +11.9% | ||
Operating | 10,870 | ▲3,234 | +2,228 | |
profit | ▲22.9% | +25.8 | ||
R&D | 3,853 | +1,193 | +122 | |
+44.9% | +3.3% | |||
(Explanation of Y/Y changes)
- Reagents: Grew in sales of COVID testing-related reagents, while sales of general research reagents remained firm.
- Instruments: Sales of PCR equipment and single-cellanalysis equipment remained the same level as the previous fiscal year.
- CDMO: Lower sales related to COVID vaccines and large-scale genome analysis projects
- Gene therapy: Sales of GMP grade reagents increased.
- Operating profit: Gross profit declined due to product mix and other factors. Operating profit decreased due to aggressive investment in R&D, etc.
2 | [1] Including in vitro diagnostics |
[2] Sales of GMP grade reagents, were reclassified from "Reagents" to "Gene Therapy" from the fiscal year under review. |
The 2nd Quarter; Operating Profit
Y/Y | Previous forecast | ||||||||||||||||||||||||||||||||||
disclosed on May 12, 2022 | |||||||||||||||||||||||||||||||||||
FY2021 | FY2021 | ||||||||||||||||||||||||||||||||||
FY2022 | 141 | Previous | 86 | ||||||||||||||||||||||||||||||||
Forecast | |||||||||||||||||||||||||||||||||||
22/ 3期 | 前期回初予想 | ||||||||||||||||||||||||||||||||||
売 | Sales | 売 | Sales | ||||||||||||||||||||||||||||||||
▲5 | +25 | ||||||||||||||||||||||||||||||||||
上 Sales | 上 Sales | ||||||||||||||||||||||||||||||||||
売 | 売上差 | 売 | 売上差 | ||||||||||||||||||||||||||||||||
profit上 | profit | ||||||||||||||||||||||||||||||||||
総Composition | 総Composition | ||||||||||||||||||||||||||||||||||
総 | ▲21 | 上 | ▲9 | ||||||||||||||||||||||||||||||||
総Composition | |||||||||||||||||||||||||||||||||||
Composition | |||||||||||||||||||||||||||||||||||
利 構成差 | 利 構成差 | ||||||||||||||||||||||||||||||||||
益 | 益 | ||||||||||||||||||||||||||||||||||
利 | 利 | ||||||||||||||||||||||||||||||||||
Gross益 | Gross | ||||||||||||||||||||||||||||||||||
Exchange | +12 | 益 | +7 | ||||||||||||||||||||||||||||||||
Exchange | |||||||||||||||||||||||||||||||||||
為替差 | 為替差 | ||||||||||||||||||||||||||||||||||
R&D | ▲11 | R&D | ▲1 | ||||||||||||||||||||||||||||||||
研究開発費 | 研究開発費 | ||||||||||||||||||||||||||||||||||
Personnel* | ▲4 | Personnel* | ▲2 | ||||||||||||||||||||||||||||||||
⼈件費※ | ⼈件費※ | ||||||||||||||||||||||||||||||||||
▲1 | |||||||||||||||||||||||||||||||||||
Other | Other | +3 | |||||||||||||||||||||||||||||||||
その他経費 | その他経費 | ||||||||||||||||||||||||||||||||||
FY2023 | 108 | FY2023 | 108 | ||||||||||||||||||||||||||||||||
23/ 期 | 23/03期 | ||||||||||||||||||||||||||||||||||
100 | 120 | 140 | 億円) | 80 | 100 (100 million yen) | ||||||||||||||||||||||||||||||
(100 million yen) |
3 * Excluding R&D personnel expenses
The 2nd Quarter; Reagents
Actual net sales | Sales performance by region | ||||||||||||
(100 million yen) | |||||||||||||
300 | |||||||||||||
249 | |||||||||||||
275 | FY2022 | ||||||||||||
COVID | |||||||||||||
22/03期 | |||||||||||||
249 | 138 | 為替 | +15 | ||||||||||
General research | |||||||||||||
Exchange | |||||||||||||
120 | ⽇本 | +27 | |||||||||||
200 | Japan | ||||||||||||
⽶国 | +8 | ||||||||||||
U.S. | |||||||||||||
China | ▲6 | ||||||||||||
114 | 129 | 137 | 中国 | ||||||||||
欧州 | |||||||||||||
100 | 40 | 129 | Europe | ▲19 | |||||||||
韓国 | 0 | ||||||||||||
89 | Korea | ||||||||||||
India印度 | 0 | ||||||||||||
FY2023 | 275 | ||||||||||||
0 | 23/03期 | ||||||||||||
20/03FY2020期 21/03FY2021期 22/FY20223期 23/FY2023期 | 240 | 300 | |||||||||||
(100 million yen) | |||||||||||||
4 | Graphs are displayed reflecting the reclassification of sales of GMP grade reagents, etc. |
The 2nd Quarter; CDMO
Actual net sales
(100 million yen) | ||||||
50 | 47 | |||||
Others | 3 | |||||
Gene analysis & testing | ||||||
40 | Regenerative medicine | 15 | ||||
356 | 313 | |||||
30 | 11 | |||||
222 | 28 | 8 | ||||
20 | 20 | |||||
8 | 17 | |||||
10 11
0
20/03FY2020期 21/03FY2021期 22/03FY2022期 23/03FY2023期
5
Regenerative medicine
- Sales decreased due to a decline in COVID vaccine- related contracts, despite robust sales of vector production, cell processing, and quality testing
Gene analysis and testing
- Decreased in sales due to the impact of the completion of large-scale genome analysis projects such as human whole genome analysis.
Contents
- Consolidated Financial Results for the Second Quarter Ended September 30, 2022
- Consolidated Financial Forecast for the Year Ending March 31, 2023
- Business Progress and Future Measures
6
Consolidated Financial Forecast for FY2023
(for the Year Ending March 31, 2023)
FY2023 | Y/Y | Comparison | |||
Full-year | with May 12 | ||||
(millions yen) | forecast | ||||
Net sales | 77,800 | +10,100 | +22,500 | ||
+14.9% | +40.7% | ||||
[1] | 65,106 | +12,626 | +24,095 | ||
Reagents | +24.1% | +58.8% | |||
Instruments | 1,716 | +197 | +244 | ||
+13.0% | +16.6% | ||||
CDMO | 8,356 | ▲3,070 | ▲1,855 | ||
▲26.9% | ▲18.2% | ||||
Gene [2] | 2,621 | +346 | +15 | ||
Therapy | +15.2% | +0.6% | |||
Gross | 43,731 | ▲5,480 | +5,875 | ||
profit | ▲11.1% | +15.5% | |||
Operating | 19,000 | ▲9,902 | +4,000 | ||
profit | ▲34.3% | +26.7 | |||
R&D | 8,713 | +2,604 | +893 | ||
+42.6% | +11.4% | ||||
(Explanation of Y/Y changes)
- Reagents: Significant growth in COVID testing-related reagents, steady growth in general research reagents
- Instruments: PCR equipment sales down slightly, single-cell analysis equipment sales up
- CDMO: COVID vaccine-related contract and large-scale genome analysis project-related contract sales decreased
- Gene Therapy: Sales of GMP grade reagents increased
- Operating profit: Gross profit decreased due to product mix and other factors. Operating income decreased due to aggressive investment in R&D, etc.
7 | [1] Including in vitro diagnostics |
[2] Sales of GMP grade reagents, were reclassified from "Reagents" to "Gene Therapy" from the fiscal year under review. |
Full-year Forecast; Operating Profit
Y/Y | Previous forecast | |
disclosed on May 12, 2022 | ||
Gross profit
FY2022 | 289 | Previous | |||||||||||||||||||
150 | |||||||||||||||||||||
forecast | |||||||||||||||||||||
期初予想 | |||||||||||||||||||||
22/03期 | 5⽉12⽇予想 | ||||||||||||||||||||
Sales | +42 | Sales | |||||||||||||||||||
+149 | |||||||||||||||||||||
売上差 | profit上 | 売上差 | |||||||||||||||||||
構成差 | 構成差 | ||||||||||||||||||||
売 | |||||||||||||||||||||
Composition | ▲121 | 総Composition | ▲110 | ||||||||||||||||||
利 | |||||||||||||||||||||
Gross | |||||||||||||||||||||
Exchange | +24 | 益 | +20 | ||||||||||||||||||
Exchange | |||||||||||||||||||||
為替差 | 為替差 | ||||||||||||||||||||
R&D | ▲26 | R&D | ▲8 | ||||||||||||||||||
研究開発費 | 研究開発費 | ||||||||||||||||||||
▲11 | ▲9 | ||||||||||||||||||||
Personnel*⼈件費※ | Personnel*⼈件費※ | ||||||||||||||||||||
Other | ▲7 | ||||||||||||||||||||
Other | ▲1 | ||||||||||||||||||||
その他経費 | その他経費 | ||||||||||||||||||||
FY2023 | FY2023 | ||||||||||||||||||||
190 | 190 | ||||||||||||||||||||
23/03期 | 23/03期 | ||||||||||||||||||||
forecast | forecast | ||||||||||||||||||||
予想 | 予想 | ||||||||||||||||||||
100 | 200 | 300 | (億円) | 100 | 200 | 300 (億円) | |||||||||||||||
(100 million yen) | (100 million yen) |
8 * Excluding R&D personnel expenses
Full-year Forecast;
Reagents and Instruments
Actual Net Sales and Forecast | Reagents | ||||||||
(100 million yen) | MMP2023 | 651 | | COVID: In addition to PCR diagnostic reagents, | |||||
sales are expected to increase significantly due | |||||||||
600 | COVID | 524 | 342 | to a significant contribution from antigen | |||||
General research | testing kits. | ||||||||
400 | 256 | | General research: Overall sales are forecast to | ||||||
339 | |||||||||
283 | increase Y/Y, despite regional differences and | ||||||||
236 | 225 | ||||||||
130 | 308 | the impact of foreign exchange rates. Forecast | |||||||
200 | 236 | 209 | 268 | to achieve the final-year targets of the | |||||
medium-term management plan FY2023 | |||||||||
0 | (MMP2023). | ||||||||
実績 | 中計 | 実績 | 実績 | 中計 予想 | Instruments | ||||
Actual | MMP2023 Actual | Actual | MMP2023 | Forecast | |||||
(100 million yen) | 22 | ||||||||
Sales of PCR equipment was consistent with | |||||||||
20 | 17 | 15 | 17 | | |||||
12 | the preceding period due to COVID testing- | ||||||||
11 | related demand and other factors. Expected to | ||||||||
10 | increase overall sales due to growth in single- | ||||||||
cell analysis-related equipment. | |||||||||
Targets for the final year of the MMP2023 are | |||||||||
0 | Actual | MMP2023 Actual | Actual | MMP2023中計 | Forecast | not expected to be achieved. | |||
実績 | 中計 | 実績 | 実績 | 予想 | |||||
20/03期 | 21/03期 | 22/ 3 | 23/ | 期 | |||||
FY2020 | FY2021 | FY2022期 | FY2023 | ||||||
9 | Graphs are displayed reflecting the reclassification of sales of GMP grade reagents, etc. |
This is an excerpt of the original content. To continue reading it, access the original document here.